Small for gestational age (SGA) fetuses/neonates are characterized by the increased risk for adverse outcomes that can be reduced if the condition is identified antenatally. We have recently developed a new approach in SGA prediction that considers SGA a spectrum condition that is reflected in two dimensions: gestational age at delivery and Z score in birth weight for gestational age. The new method has a better predictive ability than the traditionally used risk-scoring systems and logistic regression models. In this prospective study in 40241 singleton pregnancies, at 19–24 weeks’ gestation, we examined the potential value of the antiangiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) and the ratio of sFlt-1 to the angiogenic placental...
Background: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and p...
Background: several studies have demonstrated that angiogenic markers can improve the clinical manag...
OBJECTIVE: We aimed to investigate how maternal serum soluble Fms-like kinase 1 (sFlt-1), placental ...
First, to investigate the additive value of second trimester placental growth factor (PlGF) for the ...
OBJECTIVE: To investigate the predictive performance of placental growth factor (PlGF) and soluble F...
Purpose: To investigate the predictive performance of placental growth factor (PlGF) and soluble FMS...
Small for gestational age (SGA) is common in pregnancy and it has been associated with an increase i...
BACKGROUND: Fetal growth restriction is a disorder of placental dysfunction with three to four-fold ...
Small-for-gestational-age (SGA) fetuses and neonates are at increased risk of perinatal mortality a...
Abstract Background Fetal growth restriction is a disorder of placental dysfunction with three to fo...
Background Fetal growth restriction, i.e. the restriction of genetically predetermined growth potent...
BACKGROUND: Severe early-onset fetal growth restriction (FGR) predisposes to fetal death, neonatal d...
Background Fetal growth restriction, i.e. the restriction of genetically predetermined growth potent...
We sought to assess the ratio of sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental grow...
The objective: to evaluate the clinical and prognostic value and meaning of the ratio of the anti-an...
Background: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and p...
Background: several studies have demonstrated that angiogenic markers can improve the clinical manag...
OBJECTIVE: We aimed to investigate how maternal serum soluble Fms-like kinase 1 (sFlt-1), placental ...
First, to investigate the additive value of second trimester placental growth factor (PlGF) for the ...
OBJECTIVE: To investigate the predictive performance of placental growth factor (PlGF) and soluble F...
Purpose: To investigate the predictive performance of placental growth factor (PlGF) and soluble FMS...
Small for gestational age (SGA) is common in pregnancy and it has been associated with an increase i...
BACKGROUND: Fetal growth restriction is a disorder of placental dysfunction with three to four-fold ...
Small-for-gestational-age (SGA) fetuses and neonates are at increased risk of perinatal mortality a...
Abstract Background Fetal growth restriction is a disorder of placental dysfunction with three to fo...
Background Fetal growth restriction, i.e. the restriction of genetically predetermined growth potent...
BACKGROUND: Severe early-onset fetal growth restriction (FGR) predisposes to fetal death, neonatal d...
Background Fetal growth restriction, i.e. the restriction of genetically predetermined growth potent...
We sought to assess the ratio of sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental grow...
The objective: to evaluate the clinical and prognostic value and meaning of the ratio of the anti-an...
Background: Preeclampsia (PE) affects 2-3% of all pregnancies and is a major cause of maternal and p...
Background: several studies have demonstrated that angiogenic markers can improve the clinical manag...
OBJECTIVE: We aimed to investigate how maternal serum soluble Fms-like kinase 1 (sFlt-1), placental ...